China Oncology ›› 2022, Vol. 32 ›› Issue (1): 1-12.doi: 10.19401/j.cnki.1007-3639.2022.01.001
• Specialists’ Commentary • Previous Articles Next Articles
ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun()
Received:
2022-01-02
Revised:
2022-01-05
Online:
2022-01-30
Published:
2022-01-24
Contact:
YU Xianjun
E-mail:yuxianjun@fudanpci.org
CLC Number:
ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021[J]. China Oncology, 2022, 32(1): 1-12.
[1] |
SIEGEL R L,, MILLER K D,, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
doi: 10.3322/caac.v71.1 |
[2] | CABASAG C J,, FERLAY J,, LAVERSANNE M, et al. Pancreatic cancer: an increasing global public health concern[J]. Gut, 2021. Online ahead of print. |
[3] |
CARIOLI G,, MALVEZZI M,, BERTUCCIO P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer[J]. Ann Oncol, 2021, 32(4): 478-487.
doi: 10.1016/j.annonc.2021.01.006 |
[4] |
SUN D,, CAO M,, LI H, et al. Cancer burden and trends in China: a review and comparison with Japan and South Korea[J]. Chin J Cancer Res, 2020, 32(2): 129-139.
doi: 10.21147/j.issn.1000-9604.2020.02.01 |
[5] |
MIZRAHI J D,, SURANA R,, VALLE J W, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020.
doi: 10.1016/S0140-6736(20)30974-0 |
[6] |
KLEIN A P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 493-502.
doi: 10.1038/s41575-021-00457-x |
[7] |
MOCCI E,, KUNDU P,, WHEELER W, et al. Smoking modifies pancreatic cancer risk loci on 2q21.3[J]. Cancer Res, 2021, 81(11): 3134-3143.
doi: 10.1158/0008-5472.CAN-20-3267 |
[8] |
HUANG B Z,, PANDOL S J,, JEON C Y, et al. New-onset diabetes, longitudinal trends in metabolic markers, and risk of pancreatic cancer in a heterogeneous population[J]. Clin Gastroenterol Hepatol, 2020, 18(8): 1812-1821. e1817.
doi: 10.1016/j.cgh.2019.11.043 |
[9] | CHAN T T,, TSE Y K,, LUI R N, et al. Fatty pancreas is independently associated with subsequent diabetes mellitus development: a 10-year prospective cohort study[J]. Clin Gastroenterol Hepatol, 2021. Online ahead of print. |
[10] | SCHWARTZ N R M,, MATRISIAN L M,, SHRADER E E, et al. Potential cost-effectiveness of risk-based pancreatic cancer screening in patients with new-onset diabetes[J]. J Natl Compr Canc Netw, 2021: 1-9. |
[11] |
GIRI B,, SETHI V,, MODI S, et al. Heat shock protein 70 in pancreatic diseases: friend or foe[J]. J Surg Oncol, 2017, 116(1): 114-122.
doi: 10.1002/jso.v116.1 |
[12] |
QIAN W,, CHEN K,, QIN T,, et al. The EGFR-HSF 1 axis accelerates the tumorigenesis of pancreatic cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 25.
doi: 10.1186/s13046-020-01823-4 |
[13] |
DEL POGGETTO E,, HO I L,, BALESTRIERI C, et al. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis[J]. Science, 2021, 373(6561): eabj0486.
doi: 10.1126/science.abj0486 |
[14] |
TSANG E S,, TOPHAM J T,, KARASINSKA J M, et al. Delving into early-onset pancreatic ductal adenocarcinoma: how does age fit in?[J]. Clin Cancer Res, 2021, 27(1): 246-254.
doi: 10.1158/1078-0432.CCR-20-1042 |
[15] |
OPITZ F V,, HAEBERLE L,, DAUM A, et al. Tumor microenvironment in pancreatic intraepithelial neoplasia[J]. Cancers (Basel), 2021, 13(24): 6188.
doi: 10.3390/cancers13246188 |
[16] |
HAYASHI A,, HONG J,, IACOBUZIO-DONAHUE C A. The pancreatic cancer genome revisited[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 469-481.
doi: 10.1038/s41575-021-00463-z |
[17] |
SIMANSHU D K,, NISSLEY D V,, MCCORMICK F. RAS proteins and their regulators in human disease[J]. Cell, 2017, 170(1): 17-33.
doi: 10.1016/j.cell.2017.06.009 |
[18] | KRISHNAN T,, ROBERTS-THOMSON R,, BROADBRIDGE V, et al. Targeting mutated KRAS genes to treat solid tumours[J]. Mol Diagn Ther, 2021. Online ahead of print. |
[19] |
CANON J,, REX K,, SAIKI A Y, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity[J]. Nature, 2019, 575(7781): 217-223.
doi: 10.1038/s41586-019-1694-1 |
[20] |
SATURNO G,, LOPES F,, NICULESCU-DUVAZ I, et al. The paradox-breaking PANraf plus src family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers[J]. Ann Oncol, 2021, 32(2): 269-278.
doi: 10.1016/j.annonc.2020.10.483 |
[21] |
WANG J,, CHEN Y,, HUANG C, et al. Valosin-containing protein stabilizes mutant p53 to promote pancreatic cancer growth[J]. Cancer Res, 2021, 81(15): 4041-4053.
doi: 10.1158/0008-5472.CAN-20-3855 |
[22] |
KASSARDJIAN A,, WANG H L. SMAD4-expressing pancreatic ductal adenocarcinomas have better response to neoadjuvant therapy and significantly lower lymph node metastasis rates[J]. Pancreas, 2020, 49(9): 1153-1160.
doi: 10.1097/MPA.0000000000001636 |
[23] |
WANG C,, ZHANG T,, LIAO Q, et al. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation[J]. Protein Cell, 2021, 12(2): 128-144.
doi: 10.1007/s13238-020-00760-4 |
[24] |
GRANT R C,, DENROCHE R,, JANG G H, et al. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma[J]. Gut, 2021, 70(10): 1894-1903.
doi: 10.1136/gutjnl-2020-320730 |
[25] |
HSU F C,, ROBERTS N J,, CHILDS E, et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene[J]. JAMA Oncol, 2021, 7(11): 1664-1668.
doi: 10.1001/jamaoncol.2021.3701 |
[26] |
SCARPA A,, REAL F X,, LUCHINI C. Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management[J]. Gut, 2018, 67(9): 1561-1563.
doi: 10.1136/gutjnl-2018-316151 |
[27] |
FUJIKURA K,, HOSODA W,, FELSENSTEIN M, et al. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions[J]. Gut, 2021, 70(5): 928-939.
doi: 10.1136/gutjnl-2020-321217 |
[28] |
GUPTA V K,, SHARMA N S,, DURDEN B, et al. Hypoxia-driven oncometabolite L-2HG maintains stemness-differentiation balance and facilitates immune evasion in pancreatic cancer[J]. Cancer Res, 2021, 81(15): 4001-4013.
doi: 10.1158/0008-5472.CAN-20-2562 |
[29] |
MEHRA S,, DESHPANDE N,, NAGATHIHALLI N. Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress[J]. Cancers (Basel), 2021, 13(17): 4434.
doi: 10.3390/cancers13174434 |
[30] |
BIANCUR D E,, KAPNER K S,, YAMAMOTO K, et al. Functional genomics identifies metabolic vulnerabilities in pancreatic cancer[J]. Cell Metab, 2021, 33(1): 199-210. e198.
doi: 10.1016/j.cmet.2020.10.018 |
[31] |
HU Q,, QIN Y,, JI S, et al. MTAP deficiency-induced metabolic reprogramming creates a vulnerability to cotargeting de novo purine synthesis and glycolysis in pancreatic cancer[J]. Cancer Res, 2021, 81(19): 4964-4980.
doi: 10.1158/0008-5472.CAN-20-0414 |
[32] | TSAI P Y,, LEE M S,, JADHAV U, et al. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by MTORC1[J]. Proc Natl Acad Sci U S A, 2021, 118(10): e2003014118. |
[33] |
HOSEIN A N,, BREKKEN R A,, MAITRA A. Pancreatic cancer stroma: an update on therapeutic targeting strategies[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(8): 487-505.
doi: 10.1038/s41575-020-0300-1 |
[34] |
HO W J,, JAFFEE E M,, ZHENG L. The tumour microenvironment in pancreatic cancer-clinical challenges and opportunities[J]. Nat Rev Clin Oncol, 2020, 17(9): 527-540.
doi: 10.1038/s41571-020-0363-5 |
[35] | TAKAHASHI R,, MACCHINI M,, SUNAGAWA M, et al. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression[J]. Gut, 2021, 70(2): 330-341. |
[36] |
GRÜNWALD B T,, DEVISME A,, ANDRIEUX G, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer[J]. Cell, 2021, 184(22): 5577-5592. e5518.
doi: 10.1016/j.cell.2021.09.022 |
[37] |
SCHOEPS B,, ECKFELD C,, PROKOPCHUK O, et al. TIMP1 triggers neutrophil extracellular trap formation in pancreatic cancer[J]. Cancer Res, 2021, 81(13): 3568-3579.
doi: 10.1158/0008-5472.CAN-20-4125 |
[38] |
SERRANO-POZO A,, DAS S,, HYMAN B T. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches[J]. Lancet Neurol, 2021, 20(1): 68-80.
doi: 10.1016/S1474-4422(20)30412-9 |
[39] |
KEMP S B,, CARPENTER E S,, STEELE N G, et al. Apolipoprotein e promotes immune suppression in pancreatic cancer through NF-κB-mediated production of CXCL1[J]. Cancer Res, 2021, 81(16): 4305-4318.
doi: 10.1158/0008-5472.CAN-20-3929 |
[40] |
LIU H,, SHI Y,, QIAN F. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts[J]. Adv Drug Deliv Rev, 2021, 172: 37-51.
doi: 10.1016/j.addr.2021.02.012 |
[41] |
HUTTON C,, HEIDER F,, BLANCO-GOMEZ A, et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity[J]. Cancer Cell, 2021, 39(9): 1227-1244. e1220.
doi: 10.1016/j.ccell.2021.06.017 |
[42] |
LI T J,, LI H,, ZHANG W H, et al. Human splenic ter cells: a relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma[J]. Int J Cancer, 2021, 148(7): 1756-1767.
doi: 10.1002/ijc.v148.7 |
[43] |
CAO L,, HUANG C,, CUI ZHOU D, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma[J]. Cell, 2021, 184(19): 5031-5052. e5026.
doi: 10.1016/j.cell.2021.08.023 |
[44] |
LUO G,, JIN K,, DENG S, et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188409.
doi: 10.1016/j.bbcan.2020.188409 |
[45] | SINGHI A D,, WOOD L D. Early detection of pancreatic cancer using DNA-based molecular approaches[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 457-468. |
[46] |
MAJUMDER S,, TAYLOR W R,, FOOTE P H, et al. High detection rates of pancreatic cancer across stages by plasma assay of novel methylated DNA markers and CA19-9[J]. Clin Cancer Res, 2021, 27(9): 2523-2532.
doi: 10.1158/1078-0432.CCR-20-0235 |
[47] |
DINGES S S,, HOHM A,, VANDERGRIFT L A, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations[J]. Nat Rev Urol, 2019, 16(6): 339-362.
doi: 10.1038/s41585-019-0185-3 |
[48] | DE MATTEIS S,, BONAFÈ M,, GIUDETTI A M. Urinary metabolic biomarkers in cancer patients: an overview[J]. Methods Mol Biol, 2021, 2292: 203-212. |
[49] |
RADON T P,, MASSAT N J,, JONES R, et al. Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma[J]. Clin Cancer Res, 2015, 21(15): 3512-3521.
doi: 10.1158/1078-0432.CCR-14-2467 |
[50] |
YANG K S,, CIPRANI D,, O’SHEA A, et al. Extracellular vesicle analysis allows for identification of invasive IPMN[J]. Gastroenterology, 2021, 160(4): 1345-1358. e1311.
doi: 10.1053/j.gastro.2020.11.046 |
[51] | MILLIKAN K W,, DEZIEL D J,, SILVERSTEIN J C, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas[J]. Am Surg, 1999, 65(7): 618-623; discussion 623-624. |
[52] | VAN DER HEIJDE N,, LOF S,, BUSCH O R, et al. Incidence and impact of postoperative pancreatic fistula after minimally invasive and open distal pancreatectomy[J]. Surgery, 2021. Online ahead of print. |
[53] | KLOMPMAKER S,, DE ROOIJ T,, KOERKAMP B G, et al. International validation of reduced major morbidity after minimally invasive distal pancreatectomy compared with open pancreatectomy[J]. Ann Surg, 2021, 274(6): e966-e973. |
[54] |
DE ROOIJ T,, VAN HILST J,, VAN SANTVOORT H, et al. Minimally invasive versus open distal pancreatectomy (leopard) a multicenter patient-blinded randomized controlled trial[J]. Ann Surg, 2019, 269(1): 2-9.
doi: 10.1097/SLA.0000000000002979 |
[55] |
ZHANG J,, SANS M,, GARZA K Y, et al. Mass spectrometry technologies to advance care for cancer patients in clinical and intraoperative use[J]. Mass Spectrom Rev, 2021, 40(5): 692-720.
doi: 10.1002/mas.v40.5 |
[56] | KING M E,, ZHANG J,, LIN J Q, et al. Rapid diagnosis and tumor margin assessment during pancreatic cancer surgery with the masspec pen technology[J]. Proc Natl Acad Sci U S A, 2021, 118(28): e2104411118. |
[57] |
KUNZMANN V,, SIVEKE J T,, ALGÜL H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(2): 128-138.
doi: 10.1016/S2468-1253(20)30330-7 |
[58] |
DAHAN L,, WILLIET N,, LE MALICOT K, et al. Randomized phase Ⅱ trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the panoptimox-prodige 35 trial[J]. J Clin Oncol, 2021, 39(29): 3242-3250.
doi: 10.1200/JCO.20.03329 |
[59] |
SOHAL D P,, WALSH R M,, RAMANATHAN R K, et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy[J]. J Natl Cancer Inst, 2014, 106(3): dju011.
doi: 10.1093/jnci/dju011 |
[60] |
SOHAL D P S,, DUONG M,, AHMAD S A, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2021, 7(3): 421-427.
doi: 10.1001/jamaoncol.2020.7328 |
[61] |
HECHT J R,, LONARDI S,, BENDELL J, et al. Randomized phase Ⅲ study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (sequoia)[J]. J Clin Oncol, 2021, 39(10): 1108-1118.
doi: 10.1200/JCO.20.02232 |
[62] | ROJAS L A,, BALACHANDRAN V P. Scaling the immune incline in PDAC[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 453-454. |
[63] |
VONDERHEIDE R H. CD 40 agonist antibodies in cancer immunotherapy[J]. Annu Rev Med, 2020, 71: 47-58.
doi: 10.1146/med.2020.71.issue-1 |
[64] |
O’HARA M H,, O’REILLY E M,, ROSEMARIE M, et al. A phase ib study of cd40 agonistic monoclonal antibody apx005m together with gemcitabine (GEM) and nab-paclitaxel (NP) with or without nivolumab (nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients[J]. Cancer Res, 2019, 79(13): 3.
doi: 10.1158/0008-5472.CAN-18-3552 |
[65] | JIANG H,, COURAU T,, BORISON J, et al. Activating immune recognition in pancreatic ductal adenocarcinoma via autophagy inhibition, mek blockade, and CD40 agonism[J]. Gastroenterology, 2021. Online ahead of print. |
[66] |
MARELLI G,, CHARD DUNMALL L S,, YUAN M, et al. A systemically deliverable vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer[J]. J Immunother Cancer, 2021, 9(1): e001624.
doi: 10.1136/jitc-2020-001624 |
[67] |
MELISI D,, OH D Y,, HOLLEBECQUE A, et al. Safety and activity of the TGF-β receptor Ⅰ kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer[J]. J Immunother Cancer, 2021, 9(3): e002068.
doi: 10.1136/jitc-2020-002068 |
[68] |
ANWAR M Y,, WILLIAMS G R,, PALURI R K. CAR-T cell therapy in pancreaticobiliary cancers: a focused review of clinical data[J]. J Gastrointest Cancer, 2021, 52(1): 1-10.
doi: 10.1007/s12029-020-00457-1 |
[69] |
LESCH S,, BLUMENBERG V,, STOIBER S, et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours[J]. Nat Biomed Eng, 2021, 5(11): 1246-1260.
doi: 10.1038/s41551-021-00737-6 |
[70] |
GOOD C R,, AZNAR M A,, KURAMITSU S, et al. An NK-like CAR-T cell transition in CAR-T cell dysfunction[J]. Cell, 2021, 184(25): 6081-6100. e6026.
doi: 10.1016/j.cell.2021.11.016 |
[71] |
ALI A I,, WANG M,, VON SCHEIDT B, et al. A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer[J]. Clin Cancer Res, 2021, 27(22): 6222-6234.
doi: 10.1158/1078-0432.CCR-21-1141 |
[72] |
PETRELLI F,, COMITO T,, GHIDINI A, et al. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials[J]. Int J Radiat Oncol Biol Phys, 2017, 97(2): 313-322.
doi: 10.1016/j.ijrobp.2016.10.030 |
[73] |
MAHADEVAN A,, MONINGI S,, GRIMM J, et al. Maximizing tumor control and limiting complications with stereotactic body radiation therapy for pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2021, 110(1): 206-216.
doi: 10.1016/j.ijrobp.2020.11.017 |
[74] |
MUELLER A C,, PIPER M,, GOODSPEED A, et al. Induction of ADAM10 by radiation therapy drives fibrosis, resistance, and epithelial-to-mesenchyal transition in pancreatic cancer[J]. Cancer Res, 2021, 81(12): 3255-3269.
doi: 10.1158/0008-5472.CAN-20-3892 |
[75] |
REYNGOLD M,, O’REILLY E M,, VARGHESE A M, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer[J]. JAMA Oncol, 2021, 7(5): 735-738.
doi: 10.1001/jamaoncol.2021.0057 |
[76] |
ZHU X,, CAO Y,, LIU W, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial[J]. Lancet Oncol, 2021, 22(8): 1093-1102.
doi: 10.1016/S1470-2045(21)00286-2 |
[77] |
ARVIND R,, CHANDANA S R,, BORAD M J, et al. Tumor-treating fields: a fourth modality in cancer treatment, new practice updates[J]. Crit Rev Oncol Hematol, 2021, 168: 103535.
doi: 10.1016/j.critrevonc.2021.103535 |
[78] |
RIVERA F,, BENAVIDES M,, GALLEGO J, et al. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the panova phase 2 study[J]. Pancreatology, 2019, 19(1): 64-72.
doi: 10.1016/j.pan.2018.10.004 |
[79] |
BAI L,, PFEIFER T,, GROSS W, et al. Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer[J]. Front Oncol, 2021, 11: 738801.
doi: 10.3389/fonc.2021.738801 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd